{"transactions":[{"id":2033135,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-03T22:00:29.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":81250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of this option shall vest and become exercisable on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":473594,"derivative":{"exercise_price":6.65,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":81250},"source":{"system":"sec-edgar","filing":"0001209191-23-006990","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123006990/doc4.xml","form_type":"4"}},{"id":2033134,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-03T22:00:29.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of this option shall vest and become exercisable on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":392344,"derivative":{"exercise_price":4.13,"expiration_date":"2032-07-01","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001209191-23-006990","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123006990/doc4.xml","form_type":"4"}},{"id":2033133,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-03T22:00:29.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":56744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":366344,"derivative":{"exercise_price":9.15,"expiration_date":"2032-01-18","underlying":"Common Stock","underlying_shares":56744},"source":{"system":"sec-edgar","filing":"0001209191-23-006990","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123006990/doc4.xml","form_type":"4"}},{"id":2033132,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-02-03T22:00:29.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":43750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares reported in this transaction represent restricted stock units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":124006,"source":{"system":"sec-edgar","filing":"0001209191-23-006990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123006990/doc4.xml","form_type":"4"}},{"id":2033131,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-02-03T22:00:29.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The shares reported in this transaction represent restricted stock units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":65256,"source":{"system":"sec-edgar","filing":"0001209191-23-006990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123006990/doc4.xml","form_type":"4"}},{"id":2033130,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-02-03T22:00:29.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":23256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent restricted stock units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":51256,"source":{"system":"sec-edgar","filing":"0001209191-23-006990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123006990/doc4.xml","form_type":"4"}},{"id":2181870,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-08-17T22:04:19.000Z","date":"2022-08-16","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent restricted stock units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on August 16, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":43000,"source":{"system":"sec-edgar","filing":"0000899243-22-029062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322029062/doc4.xml","form_type":"4"}},{"id":2510808,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-11-16T23:36:41.000Z","date":"2021-11-16","kind":"sale","acquired":false,"shares":100,"price":21.76,"value":2176.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2288154,"source":{"system":"sec-edgar","filing":"0000899243-21-044889","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321044889/doc4.xml","form_type":"4"}},{"id":2510807,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-11-16T23:36:41.000Z","date":"2021-11-15","kind":"sale","acquired":false,"shares":6122,"price":21.9155,"value":134166.691,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.75 to $22.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2288254,"source":{"system":"sec-edgar","filing":"0000899243-21-044889","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321044889/doc4.xml","form_type":"4"}},{"id":2510806,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-11-16T23:36:41.000Z","date":"2021-11-12","kind":"sale","acquired":false,"shares":500,"price":23.1766,"value":11588.3,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.99 to $23.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2294376,"source":{"system":"sec-edgar","filing":"0000899243-21-044889","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321044889/doc4.xml","form_type":"4"}},{"id":2510805,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-11-16T23:36:41.000Z","date":"2021-11-12","kind":"sale","acquired":false,"shares":14266,"price":22.2647,"value":317628.2102,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.81 to $22.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2294876,"source":{"system":"sec-edgar","filing":"0000899243-21-044889","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321044889/doc4.xml","form_type":"4"}},{"id":2721080,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-05-10T21:28:16.000Z","date":"2021-05-10","kind":"sale","acquired":false,"shares":150000,"price":22.75,"value":3412500.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2309142,"source":{"system":"sec-edgar","filing":"0001209191-21-031337","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121031337/doc4.xml","form_type":"4"}},{"id":2779478,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-03-18T21:08:09.000Z","date":"2021-03-16","kind":"sale","acquired":false,"shares":3025,"price":30.0003,"value":90750.9075,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.95 to $30.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2459142,"source":{"system":"sec-edgar","filing":"0001209191-21-021808","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121021808/doc4.xml","form_type":"4"}},{"id":2814232,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:34:47.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":3159,"price":39.1762,"value":123757.6158,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.90 to $39.615. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2462167,"source":{"system":"sec-edgar","filing":"0001209191-21-017527","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121017527/doc4.xml","form_type":"4"}},{"id":2814231,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:34:47.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":6359,"price":38.4607,"value":244571.5913,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.89 to $38.86. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2465326,"source":{"system":"sec-edgar","filing":"0001209191-21-017527","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121017527/doc4.xml","form_type":"4"}},{"id":2839624,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-24T00:43:43.000Z","date":"2021-02-23","kind":"sale","acquired":false,"shares":800,"price":40.5594,"value":32447.52,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.21 to $41.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2471685,"source":{"system":"sec-edgar","filing":"0001209191-21-013484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121013484/doc4.xml","form_type":"4"}},{"id":2839623,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-24T00:43:43.000Z","date":"2021-02-23","kind":"sale","acquired":false,"shares":1907,"price":39.5898,"value":75497.7486,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.12 to $40.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2472485,"source":{"system":"sec-edgar","filing":"0001209191-21-013484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121013484/doc4.xml","form_type":"4"}},{"id":2839622,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-24T00:43:43.000Z","date":"2021-02-23","kind":"sale","acquired":false,"shares":1492,"price":38.8279,"value":57931.2268,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.11 to $39.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2474392,"source":{"system":"sec-edgar","filing":"0001209191-21-013484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121013484/doc4.xml","form_type":"4"}},{"id":2839621,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-24T00:43:43.000Z","date":"2021-02-22","kind":"sale","acquired":false,"shares":4506,"price":42.8394,"value":193034.3364,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.38 to $43.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2475884,"source":{"system":"sec-edgar","filing":"0001209191-21-013484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121013484/doc4.xml","form_type":"4"}},{"id":2839620,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-24T00:43:43.000Z","date":"2021-02-22","kind":"sale","acquired":false,"shares":1200,"price":41.5384,"value":49846.08,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.28 to $41.83. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2480390,"source":{"system":"sec-edgar","filing":"0001209191-21-013484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121013484/doc4.xml","form_type":"4"}},{"id":2839619,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-24T00:43:43.000Z","date":"2021-02-19","kind":"sale","acquired":false,"shares":7541,"price":41.7541,"value":314867.6681,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.41 to $42.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2481590,"source":{"system":"sec-edgar","filing":"0001209191-21-013484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121013484/doc4.xml","form_type":"4"}},{"id":2846426,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-19T13:44:24.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":1300,"price":41.5001,"value":53950.13,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.14 to $41.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2489131,"source":{"system":"sec-edgar","filing":"0000899243-21-007336","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007336/doc4.xml","form_type":"4"}},{"id":2846425,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-19T13:44:24.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":1100,"price":40.4401,"value":44484.11,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.09 to $40.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2490431,"source":{"system":"sec-edgar","filing":"0000899243-21-007336","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007336/doc4.xml","form_type":"4"}},{"id":2846424,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-19T13:44:24.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":300,"price":39.2,"value":11760.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.94 to $39.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2491531,"source":{"system":"sec-edgar","filing":"0000899243-21-007336","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007336/doc4.xml","form_type":"4"}},{"id":2850565,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-19T02:22:53.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":1386,"price":41.2806,"value":57214.9116,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.02 to $41.78. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2491831,"source":{"system":"sec-edgar","filing":"0000899243-21-007275","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007275/doc4.xml","form_type":"4"}},{"id":2850564,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-19T02:22:53.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":400,"price":39.8499,"value":15939.96,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.59 to $40.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2493217,"source":{"system":"sec-edgar","filing":"0000899243-21-007275","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007275/doc4.xml","form_type":"4"}},{"id":2850563,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-19T02:22:53.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":500,"price":38.626,"value":19313.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.28 to $39.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2493617,"source":{"system":"sec-edgar","filing":"0000899243-21-007275","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007275/doc4.xml","form_type":"4"}},{"id":2850562,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-19T02:22:53.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":200,"price":42.79,"value":8558.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.45 to $43.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2494117,"source":{"system":"sec-edgar","filing":"0000899243-21-007275","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007275/doc4.xml","form_type":"4"}},{"id":2850561,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-19T02:22:53.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":2850,"price":41.8157,"value":119174.745,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.38 to $42.23. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2494317,"source":{"system":"sec-edgar","filing":"0000899243-21-007275","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007275/doc4.xml","form_type":"4"}},{"id":2900869,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-22T00:26:23.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of this option shall vest and become exercisable on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":52000,"derivative":{"exercise_price":42.15,"expiration_date":"2031-01-19","underlying":"Common Stock","underlying_shares":52000},"source":{"system":"sec-edgar","filing":"0000899243-21-002762","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321002762/doc4.xml","form_type":"4"}},{"id":2900868,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-22T00:26:23.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":28000,"source":{"system":"sec-edgar","filing":"0000899243-21-002762","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321002762/doc4.xml","form_type":"4"}},{"id":2900867,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-22T00:26:23.000Z","date":"2020-11-30","kind":"gift","acquired":true,"shares":60394,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 30, 2020, the Reporting Person transferred 60,394 shares to the Ann M. Leen Management Trust dated 7/3/2019, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On November 30, 2020, the Reporting Person transferred 60,394 shares to the Ann M. Leen Management Trust dated 7/3/2019, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":60394,"source":{"system":"sec-edgar","filing":"0000899243-21-002762","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321002762/doc4.xml","form_type":"4"}},{"id":2900866,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-22T00:26:23.000Z","date":"2020-11-30","kind":"gift","acquired":false,"shares":60394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 30, 2020, the Reporting Person transferred 60,394 shares to the Ann M. Leen Management Trust dated 7/3/2019, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-002762","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321002762/doc4.xml","form_type":"4"}},{"id":3066005,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Series A-3 Convertible Preferred Stock","published_at":"2020-08-06T10:09:49.000Z","date":"2020-08-03","kind":"exercise","acquired":false,"shares":3631293,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2436773},"source":{"system":"sec-edgar","filing":"0000899243-20-021598","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021598/doc4.xml","form_type":"4"}},{"id":3066004,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-08-06T10:09:49.000Z","date":"2020-08-03","kind":"exercise","acquired":true,"shares":2436773,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2436773,"source":{"system":"sec-edgar","filing":"0000899243-20-021598","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021598/doc4.xml","form_type":"4"}},{"id":3072599,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":117312,"kind":"person","name":"Leen Ann M.","position":1,"cik":"0001763026","reported_name":"Leen Ann M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-31T22:43:54.000Z","date":"2020-07-29","kind":"grant","acquired":true,"shares":257600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on July 29, 2021, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":257600,"derivative":{"exercise_price":17,"expiration_date":"2030-07-29","underlying":"Common Stock","underlying_shares":257600},"source":{"system":"sec-edgar","filing":"0000899243-20-020931","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320020931/doc4.xml","form_type":"4"}}]}